Evidence map›Paper›PMID 40060894›Full record

ArticleiScience2025

Forced intracellular degradation of xenoantigens as a modality for cell-based cancer immunotherapy.

Jean Pierre Bikorimana, Roudy Farah, Jamilah Abusarah, Gabrielle Arona Mandl, Mohamed Ali Erregragui, Marina Pereira Gonçalves, Sebastien Talbot, Perla Matar, Malak Lahrichi, Nehme El-Hachem and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jean Pierre BikorimanaDepartment of Microbiology, Infectious Diseases and Immunology, Université de Montréal, Montréal, QC H3T1J4, Canada.
Roudy FarahDepartment of Microbiology, Infectious Diseases and Immunology, Université de Montréal, Montréal, QC H3T1J4, Canada.
Jamilah AbusarahDepartment of Pharmacology and Physiology, Université de Montréal, Montréal, QC H3T1J4, Canada.
Gabrielle Arona MandlDepartment of Microbiology, Infectious Diseases and Immunology, Université de Montréal, Montréal, QC H3T1J4, Canada.
Mohamed Ali ErregraguiDepartment of Microbiology, Infectious Diseases and Immunology, Université de Montréal, Montréal, QC H3T1J4, Canada.
Marina Pereira GonçalvesMolecular Biology Program, Université de Montréal, Montréal, QC H3T1J4, Canada.
Sebastien TalbotDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L3N6, Canada.
Perla MatarDepartment of Microbiology, Infectious Diseases and Immunology, Université de Montréal, Montréal, QC H3T1J4, Canada.
Malak LahrichiMolecular Biology Program, Université de Montréal, Montréal, QC H3T1J4, Canada.
Nehme El-HachemPediatric Hematology-Oncology Division, Centre Hospitalier Universitaire Sainte-Justine Research Centre, Montreal, QC H3T1C5, Canada.
Moutih RafeiDepartment of Microbiology, Infectious Diseases and Immunology, Université de Montréal, Montréal, QC H3T1J4, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Given recent leverage of mesenchymal stromal cells (MSCs) as a potent vaccination platform, we investigated whether forced degradation of an expressed experimental antigen fused to small degron sequences could prime potent antitumoral responses. Retrovirally gene-engineered MSCs were evaluated for their

Indexed as

CancerCellular therapyImmunology

Identifiers

PMID40060894
PMCPMC11889607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.